

Multidisciplinary Hepatocellular and Metastatic Liver Tumor Case Conference

Provided by Rutgers New Jersey Medical School, Department of Radiology

Interesting Cases on 2/14/2023
205 S. Orange Avenue, F-1196, Newark, NJ
2/14/2023
12:30PM to 2:00PM



Andrzej Jedynak, MD
Assistant Professor, Rutgers New Jersey Medical School

Objectives

At the conclusion of this activity, participants should be better able to:

- Identify the common presentation and management of varied liver diseases, hepatocellular carcinoma, and other hepatobiliary tumors.
- Recognize the varied imaging modalities available to direct diagnosis and treatment, as well as limitations of each. Review the optimal and adjuvant roles hepatology, interventional radiology and hepatobiliary surgery take in treatment of these diseases.

Target Audience

This activity is designed for radiologists, surgeons, internists, physician assistants, medical students and radiology residents.

Accreditation



JOINTLY ACCREDITED PROVIDER™
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, Rutgers Biomedical and Health Sciences is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians: Rutgers Biomedical and Health Sciences designates this live activity for a maximum of 1.5 *AMA PRA Category 1 Credit(s)*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Declarations

Andrzej Jedynak, MD has no relevant financial relationships with ineligible companies to disclose.

Speakers are required to disclose discussion of off-label/investigational uses of commercial products/devices in their presentation. These disclosures will be made to the audience at the time of the activity.

Planning Committee:

Drs. Chaudhry (Content Reviewer), Paterno, and Niazi have no relevant financial relationships with ineligible companies to disclose. Dr. Kumar has the following relevant financial relationship(s) with ineligible companies: Consultant: Boston Scientific; Paid Speaker: Penumbra. All of the relevant financial relationships listed have been mitigated.